General Pharmaceuticals Ltd (GPL) will broaden its export-oriented product line, company officials said.
"We are now exporting our products to 26 countries and 14 more countries will be added to our portfolio," Mahmudul Hoque, deputy manager (global marketing) of GPL told the FE recently.
He said the company consolidated its position in Sri Lanka market recently through registering and launching its 'Linaptin', a research brand for the first time in Sri Lankan pharma market.
GPL started exporting pharmaceutical finished products to Sri Lanka market from 2007 onwards, Mahmudul Hoque said.
"So far, GPL has 27 registered products in Lankan market and more products are under registration stage," the company executive said.
GPL is exporting its pharmaceutical finished formulations to Philippines, Vietnam, Hong Kong, Cambodia, Myanmar, Kenya, Ethiopia, Tanzania, Jamaica, Dominican Republic, Cameroon, Chad, Afghansitan, Macau, Somalia, Bhutan, Burkina Faso, Libya, Yemen, Niger, Nigeria, Mauritius, Maldives, Belize and Guatemala.
Another 14 countries are under consideration.
The GPL factory has been inspected & approved by the FMHACA (Food, Medicines and Health care Administration and Control Authority) of Ethiopia, TFDA (Tanzania Food and Drugs Authority) of Tanzania, Supreme Board of Drug & Medical Appliances, Yemen; Libyan Ministry of Health and PPB (Pharmacy & Poison Board), Ministry of Health, Republic of Kenya.
GPL is also working for obtaining TGA Australia and other international accreditations to explore the highly regulated pharma markets within next 5 years.
